Analyzing the Potential of a Diagnostic Tool for PD Ben Oren, Ezra Brettler, Uri Ron, and Ying Wang MKTG 897 - 401.

Slides:



Advertisements
Similar presentations
The Thyroid Incidentaloma
Advertisements

Evaluation of Movement Disorders
Dr. Declan Lyons, Consultant Psychiatrist Dr. Rebecca Quin, Senior Clinical Psychologist.
Living well with dementia: more timely diagnosis and early intervention Louise Robinson Professor of Primary Care and Ageing RCGP National Clinical Champion.
Parkinson’s Finding the cure Presentation
Parkinson’s Disease (PD)
The PARticulars of Parkinson’s Disease
Improving The Clinical Care of Children and Adolescents With Mild Traumatic Brain Injury Madeline Joseph, MD, FACEP, FAAP Professor of Emergency Medicine.
Diagnostic Method Diagnosis Diagnosis means `through knowledge` and entails acquisition of data about the patient and their complaints using the senses:
Knowledge and Attitudes Toward Genetic Testing in Parkinson’s Disease Dana Lundberg 2006.
Basal Ganglia: PATHOLOGIES Emma & Amrit. PARKINSON’S HUNTONGTON’S BALISMUS/HEMIBALISMUS ATHETOSIS WILSON’S DISEASE.
Parkinson’s disease Interventions Whitney Mundy Dr. Davis.
Brain Scan Imaging MRI, CAT, PET Imaging Interpreting Functions of the Brain through Imaging – Activity Case Study – Professional Sports and Head Trauma.
Medical Reports Dr. Nasser Al - Jarallah.
Parkinson’s Test Device Development Erin Sikkel and Tiffany Feltman.
Parkinson’s Test Device Development Erin Sikkel and Tiffany Feltman.
Is it a neurodegenerative brain disorder that progresses slowly in most people.
Chapter 17 Nursing Diagnosis
Alzheimer’s patients Caregivers Survey in Greece Dr Paraskevi Sakka Neuropsychiatrist Chairwoman, Athens Association of Alzheimer’s Disease and Related.
Parkinson’s Disease Busra Berika Yucel
Nervous System Human Body Systems Project Caroline Crinion.
The Nature of Disease.
ALZHEIMER’S DISEASE BY OLUFOLAKUNMI KEHINDE PRE-MD 1.
Investigation of Possible Periodic Paralysis (P3)
Neurodegeneration is the umbrella term for the progressive loss of structure or function of neurons, including death of neurons. Many neurodegenerative.
Neurological Manifestations of Wilson’s Disease Aleksandar Videnovic, MD, MSc Assistant Professor of Neurology Feinberg School of Medicine Northwestern.
CT & MR IMAGING OF NEUROLOGICAL DISEASES IN PREGNANCY AND PUERPERIUM.
Duodenal Levodopa Treatment in advanced Parkinson’s Disease
PARKINSON’S DISEASE By Courtney and Niral. WHAT IS IT?  Parkinson's disease (PD) is chronic and progressive movement disorder, meaning that symptoms.
Innovations in Parkinson’s Diagnosis & Treatment: A Personal Story Dr. Kenneth E. Keirstead Excellence in Aging Care Symposium September 25-27, 2013.
Analyzing the Potential of a Diagnostic Tool for PD Ben Oren, Ezra Brettler, Uri Ron, and Ying Wang MKTG
Parkinson’s Disease by Jessica Teen Health 8 Definition *Parkinson’s Disease is a disorder of the brain characterized by shaking and having difficulty.
Quantitative Detection of Parkinson's Disease Symptoms Advisor: Dr. Chris Kao Project Team: Kylen Bares Eddie Cao.
Analyzing the Potential of a Diagnostic Tool for PD Ben Oren, Ezra Brettler, Uri Ron, and Ying Wang MKTG
Basic Nursing: Foundations of Skills & Concepts Chapter 9
NEUROLOGICAL DISORDERS. Dementia  A degenerative syndrome characterized by deficits in memory, language, and mood.  The most common form: Alzheimer’s.
 Parkinson’s Disease (PD) -progressive neurodegenerative disease affecting motor ability -third most common neurologic disorder of older adults.
PARKINSON’S DISEASE BY: NICOLE MABARDI & SHAINA JOSEPH.
Neurological Disorders
By Katelyn Chaimson and Sean Guyot
The Alzheimer’s Disease Challenge: Take Your Knowledge Further ALZHEIMER’S DISEASE AND ITS MANAGEMENT: AN OVERVIEW.
Principles of Assessment and Outcome Measurement for Physical Therapists ksu. edu. sa Dr. taher _ yahoo. com Mohammed TA, Omar,
Parkinson’s Test Device Development Tiffany Feltman Erin Sikkel.
Pathogenesis and pathology of parkinsonism
Emma Hahs, Brooke Armistead, Sarah Brown, Sok Kean Khoo Department of Cell and Molecular Biology, College of Liberal Arts and Sciences, Grand Valley State.
Introduction to Pathophysiology Dr. Manzoor Ahmad Mir Assistant Professor (Immunopatholgy) College of Applied Medical Sciences Majmaah University.
Parkinson’s Disease in Africa Jacques Doumbé MD Department of Neurology Douala Laquintinie Hospital Cameroon.
Parkinson’s Disease By: Taylor Hawkins, Ana McGhee, and Morgan Zander.
Research Methodology Proposal Prepared by: Norhasmizawati Ibrahim (813750)
Introduction about Nutritional Assessment methods
Parkinson's disease ♦ Is a neurodegenerative disorder ♦ Develops around age 50 * incidence rises with age * affects 1-2% of population > age 65 ♦ Higher.
“HEALTH IS THE BEST” In the name of God. WHAT IS IT? Parkinson's disease (PD) is a chronic and progressive movement disorder, meaning that symptoms.
Patient #4 - Parkinson’s Disease
1st International Online BioMedical Conference (IOBMC 2015)
M. M. Dumitru¹∙², V.Chirita¹∙², R.Chirita¹∙²
Parkinson’s Disease Celsey and Chylee.
Falon Fiorillo & Breeanna Fournier
Parkinson's disease KRZYSZTOF NICPOŃ.
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
BRIC Neonatal Monitors Market Outlook
Parkinson's disease Parkinson's disease (PD) is the second-most common
Quantitative Detection of Parkinson's Disease Symptoms
Unit 14 – Physiological disorders
Case Studies.
ASSESSMENT IN COUNSELLING PREPAIRED BY: DR.MUNA ABDEEN ABDELRAHMAN.
Canada Cardiovascular Prosthetic Devices Market Outlook to 2020
Decision Trees Showcase
Age Friendly Places – Healthcare Sector
Defining diagnostic brain MRI markers in early MSA
Presentation transcript:

Analyzing the Potential of a Diagnostic Tool for PD Ben Oren, Ezra Brettler, Uri Ron, and Ying Wang MKTG

Client: Jafar Sabbah, CEO, Dental Devices Ltd. Technology in question: a novel computerized system for automatic quantification and measurement of time-space patterns of facial features during facial expression System is intended as a monitoring and decision support tool for the detection, and progression evaluation of medical disorders that affect the performance of facial muscles Currently system is exploited in a study on Parkinson’s Disease (PD) Project Background

Determining whether there is a real market need for an objective diagnostic computerized system for degenerative diseases such as PD This is the central question in the decision of whether to provide the inventors with seed money and bring the technology into the NGT Project Objectives

Parkinson’s Disease is the most common neurodegenerative disorder after Alzheimer's disease 4-6 million people worldwide have been diagnosed with PD ~1 million people in U.S. It is estimated that an additional 3 million people have undiagnosed PD in the U.S. The prevalence (of those diagnosed with PD) is estimated at being 0.3% in the whole population in industrialized countries Rising to 1% in those over 60 years of age 4% of the population over 80 Mean age of onset is ~60 years, but 5-10% of cases are considered young onset (cases with PD beginning between the ages of 20 and 50) U.S. incidence is ~17 per 100,000 of population per year PD Prevalence and Incidence

Physicians arrive at a diagnosis of PD using both subjective judgment and interpretation Assessing a patient’s history Performing a physical examination on the patient Requires intimate familiarity with the signs and symptoms found Accuracy of diagnosis increases with progression of the disease Current methods and scales: UPDRS UK Brain bank Criteria Gelb Criteria CAPIT Criteria Hoehn and Yahr Scale Current Diagnosis Protocol

Two of the four main symptoms must be present over a specific time period for a neurologist to consider a PD diagnosis Tremor or shaking Bradykinesia - Slowness of movement Rigidity (stiffness) of the arms, legs or trunk Postural instability - Balance problems and possible falls Brain changes that create neurodegenerative diseases are microscopic (on a chemical level) and are Not Revealed by scanning technology Current Scanning Methods: Electroencephalograms (EEGs) MRI and CAT Scans Positron Emission Tomography (PET Scan) Current Diagnosis Protocol - Cont’d

Goals of primary research:  Determine which of available methods is most preferred for both diagnosis and monitoring progression of PD  Gather more information about what specialists see as the most significant indicators of PD  Establish whether there is potential to fill an unmet need through the measurement of facial expressions Goals of primary research

According to our research based on industry standard survey (NOP World) Response to pharmacotherapy and MRIs are the most popular diagnostic and confirmatory procedures used (bottom right panel) PD patients experience more tremors (52%) than any other symptom. Wearing- off fluctuations and early morning akinesia symptoms are both seen in about a quarter of PD patients (bottom left Panel) According to NEURO’s, PCP’s are their largest referral source of PD patients. It would be very helpful if there were a reliable tool assisting PCP diagnosis. Results of primary research (1 of 4) % of PD Patients Who Undergo Each Procedure for Diagnosis % of Patients

One-on-one telephone and written interviews were conducted; focus on Neuros and PCP: Six Neurologists and one PCP were interviewed Head of Parkinson Disease Research, Education & Clinical Center in US Assistant Professor, General Internal Medicine, Johns Hopkins University Prof. Martin J. Rabey, Head of Neurology Dept., Assaf Harofe Medical Center Dr. Moshe Huberman, Deputy Head of Neurology Dept. at Meir Hospital Dr. Nirit Lev, Senior Neurologist, Rabin Medical Center Dr. Colin Klein, Head of Neurology Dept. at Meir Hospital Results of primary research (2 of 4)

Symptoms used to diagnose PD Asymmetric resting tremor Responsiveness to dopaminergic replacement therapy Cogwheel rigidity Facial asymmetry and twitching not highly prevalent, but rather facial masking (hypomimia), which can occur early Equipment used to diagnose PD Current equipment or methods used to diagnose PD are viewed as somewhat reliable, but rely on physicians’ experience for diagnosis. Some equipment requires a great deal of prep work and intensive training. Results of primary research (3 of 4)

What is the Greatest Unmet Need? A reliable tool whereby Physicians can diagnose PD accurately prior to referral to a Neurologist. Greatest challenges are diagnosing patients early on in the disease progression and differentiating PD from other atypical and secondary forms of Parkinsonism Interviewees’ opinion on the proposed method: Not asymmetry or facial twitching, which normally do not occur in PD, but Masked Faces (Hypomimia) might be useful for diagnosis; however, probably not as a biomarker of disease progression because it is treatment responsive and the degree of change over time is subtle. Results of primary research (4 of 4)

With more than 5 million diagnosed patients world-wide (and millions more not diagnosed), PD represents a very large potential market Methods for PD evaluation today are primarily based on physicians’ experience and are usually time consuming and costly  There exists a High Unmet Need for a reliable, objective diagnostic tool for PD detection and monitoring. Findings and Recommendations (1 of 2)

Findings and Recommendations (2 of 2) Main symptoms, potentially relevant for the proposed method and computerized tool, are: Hypomimia (Facial Masking) Involuntary Tremor/Twitching If the current proposed tool can theoretically detect these specific symptoms, there may be room to consider a controlled pilot study.

Demographics 1.Which category best describes your field: a researcher / involved in drug development for PD / physician or medical specialist? 2.How many patients do you diagnose as PD patients on average per month? 3.What % of patients from your diagnosis are in each of the 3 stages (Initial, bilateral, severe) of PD disease? Symptoms used to diagnose PD 4.What are the top three symptoms/traits you use to diagnose a PD patient? 5.Would you describe unusual twitches, etc. during facial expressions as a characteristic of PD for diagnosis? 6.If so – In which stages of PD would you say that the performance of facial muscles is affected? 7.How accurately and reliable do you view facial asymmetry and unusual twitches as a diagnostic tool? (e.g. are there PD patients without such phenomena?) Equipment used to diagnose PD patients 8.What are the current methods and scales you are aware of to diagnose PD patients (e.g. UPDRS)? 9.What are the current methods and scales you are aware of to monitor PD patient’s disease progression (e.g. UPDRS)? 10.If you are a physician – a)What top three methods and scales are you using to diagnose PD patients and their characteristics on a scale of 1 to 5? b)What top three methods and scales are you using to monitor PD patients’ disease progression? c)How would you characterize the level of unmet need in the available equipment for diagnosis of PD (please rate on scale of 1-5 with 1 being no need for new diagnostic tools and 10 being very high unmet need) d)Any other immediate improvements you can see in diagnosing a PD patient? e)What is the greatest challenge you face when diagnosing a PD patient? f)In your opinion, would it be possible to use facial expressions as a means to diagnose and evaluate the disease’s progression? Appendix – Interview Questions